Brain Cancer

Time to Radiotherapy After Glioblastoma Resection Affects Survival Outcomes

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date April 2, 2020

A large retrospective analysis demonstrated that a delay of 4 to 8 weeks for adjuvant radiotherapy following surgical resection of glioblastoma improved survival.

Harnessing Key Elements of the Ebola Virus in Animal Models of Glioblastoma

By

Randi Hernandez

Publish Date February 26, 2020

A glycoprotein in Ebola called the mucin-like domain may be of interest in the development of an oncolytic for brain cancer.

Maximal Resection of Glioblastomas May Up Survival

Publish Date February 21, 2020

Maximal resection of contrast-enhanced tumor linked to increased overall survival across all subgroups.

Laser-Based Imaging + AI May Diagnose Brain Tumors in OR

Publish Date January 14, 2020

Accurate diagnosis in <150 seconds in the operating room could improve decision-making during surgery.

Strategies for Managing Postradiotherapy Cerebral Radiation Necrosis in Nontarget Brain Tissue

By

Bryant Furlow

Publish Date December 11, 2019

This review seeks to shed light on a relatively common but poorly understood adverse effect of radiotherapy for primary and metastatic brain or head and neck tumors.

Brain Cancer Clinical Trials

Study Identifies Approaches to Expedite Activation of Cancer Clinical Trials

In this study, a number of barriers associated with slowing cancer trial activation at an NCI-designated cancer center were identified.

Brain Cancer Treatment Regimens

View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.

SISAQOL Consortium Recommendations for Inclusion of Patient-Reported Outcomes in Cancer Trials

SISAQOL Consortium presented their recommendations for the design and analysis of PRO data in randomized, controlled trials.

Malnutrition and Physical Inactivity May Be Crippling Clinical Trial Results

Researchers found that nutrition status and activity levels have a more significant influence on outcomes for participants in phase 1 and 2 clinical trials of cancer drugs than previously believed.

Fewer Than Half of Clinical Trials Comply With Reporting Laws

Compliance with Food and Drug Administration Amendments Act of 2007 low, not improving.